Intuitive Surgical, Inc. Net Income Jumps 24.96% in Strong Q2 2025 Performance

Intuitive Surgical, Inc. (ISRG) reported strong financial results for Q2 2025, with revenue increasing by 21% to $2.44 billion, up from $2.01 billion in Q2 2024. Net income also saw a significant rise, reaching $658.4 million, a 24.96% increase compared to $526.9 million in the same period last year. The reported revenue surpassed the analyst estimate of $2.35 billion, indicating a beat of expectations, while the diluted EPS of $1.81 also exceeded the analyst estimate of $1.93.

Key Operational Highlights

The company’s performance was significantly driven by increased procedure volumes and system placements. Approximately 775,000 da Vinci procedures were performed in Q2 2025, marking a 17% increase year-over-year. Ion procedures also saw substantial growth, with 35,300 performed, a 52% increase from Q2 2024. These procedure growths translated into an 18% increase in instruments and accessories revenue, reaching $1.47 billion.

System Placements and ASP Trends

Intuitive Surgical, Inc. placed 395 da Vinci surgical systems in Q2 2025, an increase from 341 systems in Q2 2024. This included 180 placements of the new da Vinci 5 system. The average selling price (ASP) for da Vinci surgical systems, excluding fixed-payment or usage-based operating leases, was approximately $1.50 million, up from $1.44 million in Q2 2024, primarily due to a favorable product mix. The installed base of da Vinci systems reached approximately 10,488 systems, a 14% increase from Q2 2024, contributing to a 23% rise in service revenue.

Macroeconomic and Regulatory Landscape

The company noted continued macroeconomic and geopolitical uncertainties, including tariffs and supply chain challenges, which are expected to increase costs in the second half of 2025. Specifically, new U.S. tariffs on imports from Mexico and China, despite some exemptions and reductions, are projected to raise cost of revenues. Regulatory clearances in key international markets, such as Japan and South Korea for the da Vinci 5 surgical system and SP SureForm 45 staplers, and European certification for the da Vinci 5 surgical system, are anticipated to support future growth. However, competition in the robotic-assisted surgical market and potential pricing pressures in China remain ongoing considerations.